Background：Marstacimab, previously known as PF-06741086, is a fully human monoclonal antibody IgG1 antibody that binds to the K2 domain of TFPI at nanomolar to suprananomolar concentration ranges. Non-clinical experiments demonstrated that marstacimab could enhance thrombin generation in vitro and in vivo in a concentration-dependent manner. In vitro thrombin generation assays TGAs and dilute prothrombin time dPT assays evaluating Marstacimab added to donor plasma from healthy normal volunteers and patients with haemophilia A, haemophilia B, and haemophilia A with inhibitors have all shown the ability of marstacimab to increase coagulation activity and promote haemostasis. Bleed control was demonstrated in severe injury mice models of haemophilia A and B.
